RATIONALE: The identification of patients with latent tuberculosis infection, who are at higher risk to develop active disease, is an important component of disease control. OBJECTIVES: We aim to compare the usefulness of the QuantiFERON-TB Gold in-tube assay and the tuberculin skin test to predict the development of active tuberculosis during follow-up, using positive and negative predictive values, positive likelihood ratios, and stratified level of risk. METHODS: The study included contacts of tuberculosis cases diagnosed between 2007 and 2009. All contacts included were from the first circle of exposure. Tuberculin skin test and QuantiFERON test were performed and a chest radiograph was obtained during the contact's study. MEASUREMENTS AND MAIN RESULTS: A total of 1,335 contacts were followed up for 4 years: a smear-positive index case was identified for 937 contacts, of whom 15 developed active tuberculosis and had initially presented with positive tuberculin skin test/QuantiFERON results, a normal chest radiograph, and no symptoms. The positive predictive value was 4% for QuantiFERON and 2% for the tuberculin skin test (when ≥5 mm). The probability of developing active disease was 2.36 times higher with a positive QuantiFERON, and 1.3 times higher with a positive tuberculin skin test. The positive predictive value was 17%, and the positive likelihood ratio was 7.53 for untreated contacts with a positive QuantiFERON. Stratifying according to initial QuantiFERON results showed a 6.36 times higher risk of developing active tuberculosis for patients with a QuantiFERON result greater than or equal to 10 IU/ml. Among bacillus Calmette-Guérin-vaccinated patients, a tuberculin skin test induration greater than or equal to 15 mm correlated better with a positive QuantiFERON. CONCLUSIONS: QuantiFERON results were more accurate than tuberculin skin test results in predicting tuberculosis. Although all contacts with QuantiFERON-positive results are at risk of developing tuberculosis, those with a tuberculin skin test induration greater than or equal to 15 mm and QuantiFERON greater than or equal to 10 IU/ml are at highest risk. This has important implications in the clinical management of tuberculosis contacts.
RATIONALE: The identification of patients with latent tuberculosis infection, who are at higher risk to develop active disease, is an important component of disease control. OBJECTIVES: We aim to compare the usefulness of the QuantiFERON-TB Gold in-tube assay and the tuberculin skin test to predict the development of active tuberculosis during follow-up, using positive and negative predictive values, positive likelihood ratios, and stratified level of risk. METHODS: The study included contacts of tuberculosis cases diagnosed between 2007 and 2009. All contacts included were from the first circle of exposure. Tuberculin skin test and QuantiFERON test were performed and a chest radiograph was obtained during the contact's study. MEASUREMENTS AND MAIN RESULTS: A total of 1,335 contacts were followed up for 4 years: a smear-positive index case was identified for 937 contacts, of whom 15 developed active tuberculosis and had initially presented with positive tuberculin skin test/QuantiFERON results, a normal chest radiograph, and no symptoms. The positive predictive value was 4% for QuantiFERON and 2% for the tuberculin skin test (when ≥5 mm). The probability of developing active disease was 2.36 times higher with a positive QuantiFERON, and 1.3 times higher with a positive tuberculin skin test. The positive predictive value was 17%, and the positive likelihood ratio was 7.53 for untreated contacts with a positive QuantiFERON. Stratifying according to initial QuantiFERON results showed a 6.36 times higher risk of developing active tuberculosis for patients with a QuantiFERON result greater than or equal to 10 IU/ml. Among bacillus Calmette-Guérin-vaccinated patients, a tuberculin skin test induration greater than or equal to 15 mm correlated better with a positive QuantiFERON. CONCLUSIONS: QuantiFERON results were more accurate than tuberculin skin test results in predicting tuberculosis. Although all contacts with QuantiFERON-positive results are at risk of developing tuberculosis, those with a tuberculin skin test induration greater than or equal to 15 mm and QuantiFERON greater than or equal to 10 IU/ml are at highest risk. This has important implications in the clinical management of tuberculosis contacts.
Entities:
Keywords:
IFN-γ release assays; tuberculosis; tuberculosis development
Authors: M E Castellanos; S Kirimunda; L Martinez; T Quach; H Woldu; R Kakaire; A Handel; S Zalwango; N Kiwanuka; C C Whalen Journal: Int J Tuberc Lung Dis Date: 2018-09-01 Impact factor: 2.373
Authors: Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar; Rishi K Gupta; Claire J Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C Aichelburg; Neus Altet; Roland Diel; Claudia C Dobler; Jose Dominguez; Joseph S Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M Hauri; Thomas Hermansen; James C Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W Aldridge; Andrew Copas; Molebogeng X Rangaka Journal: Nat Med Date: 2020-10-19 Impact factor: 53.440
Authors: Christine S Ho; Pei-Jean I Feng; Masahiro Narita; Jason E Stout; Michael Chen; Lisa Pascopella; Richard Garfein; Randall Reves; Dolly J Katz Journal: Lancet Infect Dis Date: 2021-09-06 Impact factor: 25.071
Authors: Neus Altet; Irene Latorre; María Ángeles Jiménez-Fuentes; José Maldonado; Israel Molina; Yoel González-Díaz; Celia Milà; Esther García-García; Beatriz Muriel; Raquel Villar-Hernández; Maisem Laabei; Andromeda-Celeste Gómez; Pere Godoy; Maria Luiza de Souza-Galvão; Segismundo Solano; Carlos A Jiménez-Ruiz; Jose Domínguez Journal: PLoS One Date: 2017-08-24 Impact factor: 3.240
Authors: Ibrahim Abubakar; Francis Drobniewski; Jo Southern; Alice J Sitch; Charlotte Jackson; Marc Lipman; Jonathan J Deeks; Chris Griffiths; Graham Bothamley; William Lynn; Helen Burgess; Bobby Mann; Ambreen Imran; Saranya Sridhar; Chuen-Yan Tsou; Vladyslav Nikolayevskyy; Melanie Rees-Roberts; Hilary Whitworth; Onn Min Kon; Pranab Haldar; Heinke Kunst; Sarah Anderson; Andrew Hayward; John M Watson; Heather Milburn; Ajit Lalvani Journal: Lancet Infect Dis Date: 2018-08-30 Impact factor: 71.421
Authors: R Villar-Hernández; I Latorre; M L De Souza-Galvão; M A Jiménez; J Ruiz-Manzano; J Pilarte; E García-García; B Muriel-Moreno; A Cantos; N Altet; J P Millet; Y González-Díaz; I Molina-Pinargote; C Prat; M Ruhwald; J Domínguez Journal: Sci Rep Date: 2019-03-08 Impact factor: 4.379
Authors: R Villar-Hernández; T Blauenfeldt; E García-García; B Muriel-Moreno; M L De Souza-Galvão; J P Millet; F Sabriá; A Sánchez-Montalvá; J Ruiz-Manzano; J Pilarte; M A Jiménez; C Centeno; C Martos; I Molina-Pinargote; Y D González-Díaz; J Santiago; A Cantos; I Casas; R M Guerola; C Prat; P Andersen; I Latorre; M Ruhwald; J Domínguez Journal: Sci Rep Date: 2020-08-06 Impact factor: 4.379